---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-007430"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2026-02-19T23:59:59+00:00"
generated_at: "2026-05-16T01:42:07.200931+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma's CDI-988 oral norovirus inhibitor to be featured at ICAR 2026

## Summary
- CDI-988 is the first oral antiviral drug candidate developed for prevention and treatment of norovirus infections.
- Company to present Phase 1b challenge study data at ICAR 2026 in Prague (Apr 27-May 1, 2026).
- No approved antiviral therapies or vaccines for norovirus; estimated $10.6B annual US economic burden.
- CDI-988 is a pan-viral protease inhibitor also targeting coronaviruses, developed using proprietary structure-based platform.

## SEC filing metadata
- accession: 0001493152-26-007430
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2026-02-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315226007430/0001493152-26-007430-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315226007430/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-007430
- JSON: https://secwatch.observer/filing/0001493152-26-007430.json
- Plain text: https://secwatch.observer/filing/0001493152-26-007430.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.